
Methods: A total of 3,031 S. aureus (SA), 924 coagulase-negative staphylococci (CoNS), 973 enterococci (ENT), 850 S. pneumoniae (SPN), 236 viridans group (VGS), and 727 β-hemolytic streptococci (BHS) from 60 medical centers were susceptibility (S) tested against LZD and comparator agents by reference broth microdilution methods. LZD-R isolates were confirmed by Etest (bioMerieux, Hazelwood, MO) and repeat reference S testing. PCR and sequencing was performed to detect mutations in 23S rRNA, L3, L4, and L22 proteins, and acquired genes (cfr, optrA).
Results: LZD activity against 6,741 GP organisms was high (99.84% S). The MIC50/90 for SA, MRSA, and MSSA was at 1/1 μg/ml. The MRSA rate which has declined each year over the last eight years was at 45.9%. For CoNS, MRSE, and MSSE the MIC50/90 for LZD was 0.5/1 μg/ml. LZD was active against all SPN and BHS with a MIC50/90 of 1/1, μg/ml and VGS with an MIC50/90 of 0.5/1 μg/ml. SPN penicillin non-susceptibility (NS; MIC, ≥0.12 μg/ml) occurred at a rate of 36.8% and ceftriaxone-NS at 1.7%. There was one LZD-R MRSA (MIC, 8 µg/ml), which harbored G2576T alterations. Among CoNS, seven S. epidermidis, 0.76% of all CoNS strains (0.75% in 2014, 0.52% in 2013, 0.92% in 2012) demonstrated LZD MIC results of ≥16 μg/ml. Four of these were from a single site (3 isolates were clonally-related); 2 of which contained cfr in addition to mutations in other drug target sites. Other CoNS had combinations of 23S rRNA/L3/L4 alterations. One E. faecalis harbored optrA, while two E. faecium had G2576T mutations in 23S rRNA.
Conclusion: These in vitro results show continued potent activity of LZD. LZD R phenotypes remain uncommon (<1%); and most isolates are S. epidermidis carrying multiple R mechanisms. cfr-carrying isolates remain rare and associated with clonal dissemination, while detection of a newer mobile resistance mechanism (optrA) emphasizes the need for monitoring.

R. K. Flamm,
Pfizer Inc.:
Research Contractor
,
Research grant
R. E. Mendes, Pfizer Inc.: Research Contractor , Research grant
H. S. Sader, Pfizer Inc.: Research Contractor , Research grant
P. A. Hogan, Pfizer Inc.: Employee , Salary